Vitro Diagnostics and HemoGenix Inc. Launch New Products at an International Stem Cell Meeting

GOLDEN & COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, and HemoGenix®, Inc. announced the launch of new high performance stem cell testing products at the International Society for Stem Cell Research annual meeting being held in San Francisco, CA this week. This meeting is being attended by over 3,000 participants from leading academic institutions and commercial stem cell firms throughout the world. The new products extend the well established HALO® assay platform for hematopoietic stem cells to now include mesenchymal stem cells and induced pluripotent stem cells (iPS) as well. These new high performance assays provide an ability to analyze stem cells for determination of quality, potency and response to toxic agents. Through a previously established alliance, these new products are jointly manufactured by Vitro and HemoGenix®, Inc. Vitro provides its specialized stem cell media and stem cells while HemoGenix® provides the LUMENESC™ and LumiSTEM™ ATP bioluminescent readout reagents and materials.